A new study suggests that diabetes medication may slow the progression of epilepsy. This development is being considered as an important step to combat the disease in the future.
According to the study, patients who used lixisenatide had a reduction in the development of motor symptoms (such as tremors and slowness of movements).
However, the study also found that 46 percent of people taking lixisenatide experienced nausea and 13 percent experienced vomiting.
For the past 30 years, the two have been trying to understand how to slow the progression of Parkinson’s disease-related symptoms over time, the study’s principal researchers, Professor Vasilius Meissner and Oliver Raskol, said in a joint statement.
He said that in this respect, the positive results of the second phase trial of Lixiparc, the decrease in the rate of increase in the motor symptoms of Parkinson’s disease during one year, is an important development.
According to the researchers, efforts will be made to confirm the encouraging results obtained in the future so that these results can be translated into practical practice.
Researchers conducted the study on 156 people who had recently been diagnosed with Parkinson’s.
